As the PD1, PDL-1 and CTLA4 receptors are coexpressed in non-tumor related tissue, a systemic down-regulation due to ICI therapy is further associated with the development of side effects, called immune-related adverse events (irAEs) [3,4]. The gene discussed is PDCD1; the disease is neoplasm.